SEO URLwww.firestrike.ai/deals/soleno-therapeutics-neurocrine-biosciences-merger-2026
mergerAnnounced · May 11, 2026Chemical Manufacturing (325)Source · CredibleArticle · Factual
Neurocrine Biosciences merges with Soleno Therapeutics
David Najork · Founding Software Engineer
Announced · Updated · 1 min read
Deal value
—
Party A
Soleno Therapeutics
NASDAQ: SLNO · Redwood City, California
Party B
Neurocrine Biosciences
Pending
Status
Pending
Neurocrine Biosciences and Soleno Therapeutics are pursuing a merger. Reported scale / consideration: Undisclosed. Status: Pending. Sector: Not specified. Target headquarters context: Redwood City, California, United States.
This page summarizes publicly available information about the transaction as of 2026-05-11. Figures and status may change as filings and press coverage update.
Soleno Therapeutics has entered into a definitive merger agreement with Neurocrine Biosciences , including a cash tender offer
Deal timeline
Announced
May 11, 2026 · sg.finance.yahoo.com
Additional milestones (proxy, vote, close) appear as filings and press updates are indexed.
Sector context
This transaction is classified in Chemical Manufacturing (325). Figures and status may change as sources update.
Sources: sg.finance.yahoo.com · Primary article · FireStrike proprietary index